Financial calendar for Zealand Pharma in 2018
Company announcement - No. 52/2017
Financial calendar for Zealand Pharma in 2018
Copenhagen, November 30, 2017 - Zealand Pharma A/S ("ZEAL") announces the following dates for the company's planned financial reporting in 2018:
7 March Full year announcement and Annual Report 2017 16 May Interim report for the first three months of 201816 August Interim report for 1st half 201815 November Interim report for the first 9 months of 2018
Zealand's Annual General Meeting will be held on April 19, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial OfficerTel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow us on Twitter @ZealandPharma or LinkedIn.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/4dbcd952-530a-49a5-9400-3021a64a8360
Source: Zealand Pharma A/SSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Hawk Law Group’s Hawk Helps Hosts Third Annual Bookbag Bash, Providing Back-to-School Supplies to More Than 500 Augusta-Area Students
- StackQuarry Opens Software Research Library Focused On the Costs That Appear After Purchase
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share